2900-27-8

Basic information

• Product Name: BOC-D-PHG-OH
• Synonyms: (2S)-[(tert-butoxycarbonyl)aMino](phenyl)ethanoic acid;(S)-2-((tert-Butoxycarbonyl)aMino)-2-phenylacetic acid;N-(tert-Butoxycarbonyl)-L-2-phenylglycine, 98.0%(LC);(S)-Boc-2-aminophenylacetic acid;Boc-L-phenylglycine99%;N-Boc-L-2-phenylglycine,99%e.e.;BOC-D-ALPHA-PHENYLGLYCINE;BOC-D-A-PHENYLGLYCINE
• CAS NO: 2900-27-8
• Molecular Formula: C₁₃H₁₇NO₄
• Molecular Weight: 251.28
• EINECS: -0
• Product Categories: Amino Acid Derivatives;Amino Acids;Phenylglycine [Phg];Unusual Amino Acids;Amino Acids (N-Protected);Biochemistry;Boc-Amino Acids;Boc-Amino acid series
• Mol File: 2900-27-8.mol
• Article Data: 85

Chemical Properties

• Melting Point: 88-91 °C
• Boiling Point: 407.2 °C at 760 mmHg
• Flash Point: 200.1 °C
• Appearance: /
• Density: 1.182 g/cm³
• Vapor Pressure: 2.32E-07mmHg at 25°C
• Refractive Index: 142 ° (C=1, EtOH)
• Storage Temp.: Store at RT.
• PKA: 3.51±0.10(Predicted)
• Water Solubility: Insoluble in water
• BRN: 3592362
• CAS DataBase Reference: BOC-D-PHG-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-D-PHG-OH(2900-27-8)
• EPA Substance Registry System: BOC-D-PHG-OH(2900-27-8)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 2900-27-8(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white crystalline powder

InChI:InChI=1/C13H17NO4/c1-13(2,3)18-12(17)14-10(11(15)16)9-7-5-4-6-8-9/h4-8,10H,1-3H3,(H,14,17)(H,15,16)/t10-/m0/s1

Upstream product

• 13303-10-1 tert-Butyl 4-nitrophenyl carbonate 
• 2835-06-5 phenylglycin 
• 102089-74-7 tert-butyl 2-hydroxy-1-phenylethylcarbamate 
• 219580-24-2 3,5-Dimethyl-pyrazole-1-carboxylic acid tert-butyl ester 
• 117681-86-4 (1R,2S,5R)-2-(1-methyl-1-phenylethyl)-5-methylcyclohexyl (tert-butoxycarbonyl)aminoacetate 
• 124-38-9 carbon dioxide 
• 155396-71-7 tert-butyl N-(phenyl(phenylsulfonyl)methyl)carbamate 
• 941602-11-5 tert-butyl N-(2-nitro-1-phenylethyl)carbamate 
• 2935-35-5 (S)-2-phenylglycine 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 186375-60-0 N-(trimethylsilyl)-N-(tert-butyloxycarbonyl)benzylamine 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 1021948-09-3 D,L-N-Boc-Phg-SEt 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 3573-13-5 6β-((Ξ)-2-tert-butoxycarbonylamino-2-phenyl-acetylamino)-penicillanic acid 
• 117194-49-7 Boc-Phg-O-iBu 
• 2900-28-9 Z-Thr(Boc-Phg-O-)-OH 
• 76219-90-4 maytansinol 3-N-tert-butoxycarbonyl-D-phenylglycinate 
• 76219-90-4 maytansinol 3-N-tert-butoxycarbonyl-L-phenylglycinate 
• 1028312-79-9 {(S)-[(S)-2-Cyclohexyl-1-((2S,4R)-4-methyl-5-oxo-tetrahydro-furan-2-yl)-ethylcarbamoyl]-phenyl-methyl}-carbamic acid tert-butyl ester 
• 3412-48-4 L-(+)-α-phenylglycine N-carboxy anhydride 
• 136354-02-4 (methoxy-phenyl-methyl)-carbamic acid tert-butyl ester 
• 145280-01-9 (1R,2S,5R)-2-(1-methyl-1-phenylethyl)-5-methylcyclohexyl (R)-2-<(tert-butoxycarbonyl)amino>-2-phenylacetate 
• 117049-13-5 (1R,2S,5R)-2-(1-methyl-1-phenylethyl)-5-methylcyclohexyl (S)-2-<(tert-butoxycarbonyl)amino>-2-phenylacetate 
• 128266-58-0 tert-Butoxycarbonylamino-phenyl-acetic acid 4-{2-[4-(2-tert-butoxycarbonylamino-2-phenyl-acetoxymethyl)-3,5-dioxo-piperazin-1-yl]-ethyl}-2,6-dioxo-piperazin-1-ylmethyl ester 
• 1061680-00-9 (6R,7R)-7-(2-tert-Butoxycarbonylamino-2-phenyl-acetylamino)-8-oxo-3-(1-trityl-1H-[1,2,3]triazol-4-ylsulfanylmethylsulfanyl)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 111652-10-9 tert-Butoxycarbonylamino-phenyl-acetic acid tert-butyl ester 
• 33125-05-2 Boc-D-Phg-OH 

Relevant articles and documents

Synthesis ofN-Boc-α-amino Acids from Carbon Dioxide by Electrochemical Carboxylation ofN-Boc-α-aminosulfones

Electrochemical reduction ofN-Boc-α-aminosulfones in DMF using an undivided cell equipped with a Pt plate cathode and an Mg rod anode under atmospheric pressure of bubbling carbon dioxide through the solution under constant current conditions resulted in a reductive C-S bond cleavage with elimination of benzenesulfinate ion generating the corresponding anion species followed by fixation of carbon dioxide to give the correspondingN-Boc-α-amino acids in moderate to good yields.

Discovery of M3Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease

In this paper, we report the discovery of dual M3 antagonist-PDE4 inhibitor (MAPI) compounds for the inhaled treatment of pulmonary diseases. The identification of dual compounds was enabled by the intuition that the fusion of a PDE4 scaffold derived from our CHF-6001 series with a muscarinic scaffold through a common linking ring could generate compounds active versus both the transmembrane M3 receptor and the intracellular PDE4 enzyme. Two chemical series characterized by two different muscarinic scaffolds were investigated. SAR optimization was aimed at obtaining M3 nanomolar affinity coupled with nanomolar PDE4 inhibition, which translated into anti-bronchospastic efficacy ex vivo (inhibition of rat trachea contraction) and into anti-inflammatory efficacy in vitro (inhibition of TNFα release). Among the best compounds, compound 92a achieved the goal of demonstrating in vivo efficacy and duration of action in both the bronchoconstriction and inflammation assays in rat after intratracheal administration.

COMPOUNDS USEFUL IN HIV THERAPY

The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.